Debug Stats | ### Total Build Time: 25 ms 47.775 KB CONCEPT_NAME gt=3 ms Completed: 3 ms rowSize= 346 bytesCONCEPT_SOLR_HIT_STATS gt=0 Completed: 0 ms rowSize= 14 bytesCONCEPT_DEFINITION gt=0 Completed: 0 ms rowSize= 333 bytes- Skipping details on:
CONCEPT_SYNONYM gt=NONE 0 Completed: 0 ms rowSize= 0 bytes - Skipping details on:
CONCEPT_TEXT gt=NONE 0 Completed: 0 ms rowSize= 0 bytes CONCEPT_SEMANTIC_TYPE gt=0 Completed: 0 ms rowSize= 187 bytes- Skipping details on:
CONCEPT_NAMESPACE gt=NONE 0 Completed: 0 ms rowSize= 0 bytes CONCEPT_PARENTS gt=0 Completed: 0 ms rowSize= 554 bytesCONCEPT_CHILDREN gt=4 ms Completed: 4 ms rowSize= 1,020 bytesCONCEPT_ANCESTRAL_ROOTS gt=0 Completed: 0 ms rowSize= 4.063 KBCONCEPT_RELATIONSHIPS gt=8 ms Completed: 8 ms rowSize= 14.807 KBCONCEPT_GENES gt=10 ms Completed: 10 ms rowSize= 25.337 KBCONCEPT_XREFS gt=0 Completed: 0 ms rowSize= 1.158 KBCONCEPT_ANCILLARY gt=0 Completed: 0 ms rowSize= 14 bytes- Reload Stats
|
Genes (25)
Species: human : 25 | |
Human | BCL10 | 8915 | B-cell CLL/lymphoma 10 | INFERRED, Score=800, UMLKSK CUI: C0023486 | Human | IFITM1 | 8519 | interferon induced transmembrane protein 1 | Leu-13 density, determined by flow cytometry, was upregulated in vitro and in vivo by IFN-alpha on malignant B cells from patients with HCL, chronic lymphocytic leukemia, and prolymphocytic leukemia. | Human | TCL1A | 8115 | T-cell leukemia/lymphoma 1A | INFERRED, Score=800, UMLKSK CUI: C0023486 | Human | D13S25 | 8101 | Disrupted in B-cell neoplasia | INFERRED, Score=800, UMLKSK CUI: C0023486 | Human | ZAP70 | 7535 | zeta-chain (TCR) associated protein kinase 70kDa | B-prolymphocytic leukemia appears biologically heterogeneous regarding IgVH mutations, ZAP-70 and CD38 expression, showing a pattern distinct from that of other lymphoproliferative disorders | Human | TRA@ | 6955 | | INFERRED, Score=800, UMLKSK CUI: C0023486 | Human | TAL1 | 6886 | T-cell acute lymphocytic leukemia 1 | INFERRED, Score=800, UMLKSK CUI: C0023486 | Human | SELL | 6402 | selectin L | Most of these cases may represent leukemic non-Hodgkins lymphoma (NHL) other than B-cell chronic lymphocytic leukemia (BCLL); nonetheless, some investigators still advocate the term ;CD5-negative BCLL.; Because adhesion molecule (AdMol) expression patterns reflect the biology of lymphoid neoplasms, we studied a series of 106 B-cell lymphoproliferative disorders, including CD5+ BCLL (n = 56), NHL other than BCLL (n = 35), and CD5-/CD10- CBL (excluding hairy cell leukemia and prolymphocytic leukemia) with no prior history of NHL (n = 15) for expression of components of the very late antigen-4 complex (alpha4/beta1 integrin (CD49d/CD29)), components of the mucosal addressin-cell adhesion molecule receptor (alpha4(CD49d)/beta7 integrin), and L-selectin (CD62L). | Human | RAB1A | 5861 | RAB1A, member RAS oncogene family | INFERRED, Score=800, UMLKSK CUI: C0023486 | Human | ABCB4 | 5244 | ATP-binding cassette, sub-family B (MDR/TAP), member 4 | Expression of the mdr3 gene in prolymphocytic leukemia: association with cyclosporin-A-induced increase in drug accumulation. Here we report high levels of expression of mdr3 gene sequences in leukemic cells from 6 out of 6 patients with prolymphocytic leukemia (PLL). | Human | MYBL1 | 4603 | v-myb avian myeloblastosis viral oncogene homolog-like 1 | A-myb was undetectable in 4 prolymphocytic leukemias (PLL) but was strongly expressed in 5/20 (25%) of chronic lymphocytic leukemia (CLL) samples. | Human | MTCP1 | 4515 | mature T-cell proliferation 1 | INFERRED, Score=800, UMLKSK CUI: C0023486 | Human | ITGB2 | 3689 | integrin, beta 2 (complement component 3 receptor 3 and 4 subunit) | INFERRED, Score=800, UMLKSK CUI: C0023486 | Human | ITGAL | 3683 | integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide) | INFERRED, Score=800, UMLKSK CUI: C0023486 | Human | HEXB | 3074 | hexosaminidase B (beta polypeptide) | Four acid hydrolases, acid phosphatase (AP), alpha-naphthyl acetate esterase (ANAE), beta-glucuronidase, and N-acetyl-beta-glucosaminidase, were determined cytochemically in peripheral blood lymphocytes from 50 patients with B and T chronic lymphocytic and prolymphocytic leukemias (CLL, PLL) and related disorders. | Human | FMOD | 2331 | fibromodulin | INFERRED, Score=800, UMLKSK CUI: C0023486 | Human | FCER2 | 2208 | Fc fragment of IgE, low affinity II, receptor for (CD23) | Based on morphology, of the CD23, 16 (70%) were diagnosed with mantle cell leukemia (MCL) was diagnosed in 16 (70%) CD23- patients, 3 (13%) with splenic marginal-zone leukemia, 3 (13%) with prolymphocytic leukemia (PLL) or PLL/CLL, and 1 (4%) with CLL. In prolymphocytic leukemias (PL), CD5 and CD23 antigens were constantly absent while lower CD19 and CD22 ABC levels were observed. | Human | CSF2RA | 1438 | colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage) | Using sensitive triple-layer immunophenotypic techniques, we show here that both the alpha and beta c chains of the GMR are expressed on hairy cells (HCs) and myelomatous plasma cells (PCs), but not on chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia (PLL) lymphocytes. | Human | CD38 | 952 | CD38 molecule | B-prolymphocytic leukemia appears biologically heterogeneous regarding IgVH mutations, ZAP-70 and CD38 expression, showing a pattern distinct from that of other lymphoproliferative disorders Peripheral blood mononuclear cells from 24 patients with prolymphocytic leukemia (PLL) were isolated using a Ficoll-Hypaque gradient and stained by indirect immunofluorescence using a wide panel of monoclonal antibodies against B cell restricted and associated antigens, including HLA DR (Ia), CD19, CD21 (C3dR) surface membrane immunoglobulin (Slg), CD10 (CALLA), C3b, B5, CD25 (TAC), PCA1, T9, and T10. | Human | CD33 | 945 | CD33 molecule | Four kinds of immunotherapy for acute leukemia are under investigation: (1) monoclonal antibodies, among them, Mylotarg (cytotoxic antibiotic calicheamicin linked to CD33 Mab) is given for the treatment of refractory or relapsed acute myeloid leukemia and molecular relapse in acute promyelocytic leukemia with good results, Campath-1H (antiCD52 Mab) is administered in the treatment of prolymphocytic leukemia and Rituximab (anti-CD20 Mab) in B-PLL with high complete remission rates. | Human | TNFSF8 | 944 | tumor necrosis factor (ligand) superfamily, member 8 | INFERRED, Score=800, UMLKSK CUI: C0023486 | Human | CD22 | 933 | CD22 molecule | In prolymphocytic leukemias (PL), CD5 and CD23 antigens were constantly absent while lower CD19 and CD22 ABC levels were observed. | Human | MS4A1 | 931 | membrane-spanning 4-domains, subfamily A, member 1 | We report a case of a woman with acute prolymphocytic leukemia who received chemotherapy containing fludarabine and cyclophosphamide, followed by the CD 20 monoclonal antibody, rituximab. | Human | ATM | 472 | ataxia telangiectasia mutated | INFERRED, Score=800, UMLKSK CUI: C0023486 | Human | IL14~withdrawn | 0 | | Human high molecular weight-B cell growth factor (HMW-BCGF) (60 kD) stimulates activated normal B cells, B cell precursor acute lymphoblastic leukemia (BCP-ALL) cells, hairy cell leukemia (HCL) cells, prolymphocytic leukemia (PLL) cells, and chronic lymphocytic leukemia (CLL) cells. |
|